PACTUS:不适合标准化疗放疗的肛鳞癌患者两周放疗方案的单中心回顾性经验
本研究回顾性分析乌普萨拉大学医院2017–2025年接受姑息性放疗的肛鳞癌患者,主要队列接受PACTUS方案(40 Gy/10次,两周)。35例中28例接受PACTUS,中位总生存30个月,方案在该选定体弱老年队列中可行,但需前瞻性评估。
要点
- PACTUS为两周40 Gy/10次姑息放疗方案,用于不适合根治性放化疗的肛鳞癌患者。
- PACTUS队列中位总生存30个月,但治疗选择受患者体能和预期耐受影响,比较仅为描述性。
- 临床反应和症状结局仅部分患者可评估,毒性未系统前瞻性采集。
核心结论
- PACTUS方案在主要為老年且合并症多的选定肛鳞癌患者中可行,值得前瞻性评估。
研究设计与样本
- 单中心回顾性研究,回顾2017–2025年乌普萨拉大学医院连续接受姑息性放疗的肛鳞癌患者。
- 主要队列接受PACTUS(40 Gy/10次),另纳入短程和Quad Shot方案作为背景病例系列。
- 共735例肛鳞癌患者中35例(4.7%)接受姑息性放疗:28例PACTUS、4例短程、3例Quad Shot。
主要发现
- PACTUS队列中位年龄80岁(范围60–97),25例(71%)为女性,30例(86%)ECOG体能状态≥3。
- PACTUS队列中位总生存30个月;截至2026年4月2日,PACTUS死亡14/28(50%),短程4/4(100%),Quad Shot 2/3(67%)。
- 存活患者中位随访20个月(范围4–71个月)。
- 临床反应仅15/35(43%)可评估,症状结局仅13/35(37%)可评估,不具全队列代表性。
- PACTUS中24/28例接受选择性淋巴结照射;毒性未系统采集或前瞻性分级。
关键数值与推荐
- PACTUS方案:40 Gy分10次,两周内完成。
- 治疗选择基于患者体能、预期耐受、预后、后勤和患者偏好。
临床怎么用
- 对于不适合根治性放化疗的肛鳞癌患者,PACTUS可作为姑息放疗选择,旨在缓解症状并可能获得持久局部控制。
- 因治疗选择受适应症影响,不同方案间比较仅为描述性,不能确立比较有效性或生存获益。
局限性
- 回顾性单中心设计,样本量小(姑息放疗共35例,PACTUS 28例)。
- 临床反应和症状结局仅部分患者可评估,不具全队列代表性。
- 毒性未系统采集或前瞻性分级。
- 治疗选择非随机,方案间比较不能确立比较有效性或生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anal squamous cell carcinoma (ASCC) is rare, and optimal treatment for patients unsuitable for definitive chemoradiotherapy remains undefined. This study describes PACTUS (Palliative Anal Cancer Treatment Uppsala Style), a two-week radiotherapy regimen designed for symptom relief and potentially durable local control. METHODS: We retrospectively reviewed consecutive patients with ASCC treated with palliative-intent radiotherapy at Uppsala University Hospital (2017-2025). The principal cohort received PACTUS (40 Gy in 10 fractions). Patients treated with Short-course or Quad Shot were included as contextual case series. Treatment selection was based on patient fitness, anticipated tolerance, prognosis, logistics, and patient preference. Overall survival (OS) was measured from radiotherapy initiation. Clinical response, symptom outcomes, and adverse effects were summarized using evaluable denominators. RESULTS: Of 735 patients treated for ASCC, 35 (4.7%) received palliative-intent radiotherapy: 28 received PACTUS, 4 Short-course, and 3 Quad Shot. The median age was 80 years (range, 60-97), 25 (71%) were women, and 30 (86%) had an ECOG performance status ≥3. Elective nodal irradiation was delivered to 24/28 patients in PACTUS. The median OS in PACTUS cohort was 30 months. At the data cut-off (April 2, 2026), 20 patients had died: 14/28 (50%) in PACTUS, 4/4 (100%) in Short-course, and 2/3 (67%) in Quad Shot. Median follow-up among surviving patients was 20 months (range, 4-71 months). Clinical response was evaluable in 15/35 (43%) patients and symptom outcomes in 13/35 (37%); therefore, these findings were not considered representative of the full cohort. Toxicity was not collected systematically or graded prospectively. CONCLUSIONS: PACTUS was feasible in this selected cohort of predominantly elderly and comorbid patients and warrants prospective evaluation. However, because treatment selection was guided by patient fitness and anticipated treatment tolerance, comparisons between the alternative regimens are descriptive only and cannot establish comparative effectiveness or a survival benefit.
引用
- Delgado CB, Olsson E, Norrlid O, et al. PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy-a retrospective single-centre experience. Clin Transl Radiat Oncol. 2026. PMID: 42787148. doi:10.1016/j.ctro.2026.101280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。